ArticleMolecular cancer therapeutics2011

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Dong Hoon Shin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.